Aktienanalyse zu TriSalus Life Sciences Inc (TLSI)TLSITriSalus Life Sciences Inc

TriSalus Life Sciences, Inc. is an oncology-focused medical technology company. It is seeking to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technological applications. Its delivery method, Pressure-Enabled Drug Delivery (PEDD), modulates pressure and flow within blood vessels to improve intravascular therapeutic delivery into tumors, thereby increasing the likelihood of tumor response in comparison to conventional delivery technologies. Its on-market TriNav Infusion System using PEDD technology, is being used for interventional radiology procedures, commonly transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or in patients with liver metastases. TriNav is a device with a novel (PEDD) delivery method. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

TriSalus Life Sciences Inc is not a strong buy right now due to its current price of $4.83, which is significantly below the analyst price target of $8. However, the stock has a low RSI of 26.08, indicating it may be oversold. The company has shown a gross margin of 86% in recent quarters, suggesting strong profitability potential if it can stabilize revenues. The main risk is the net income loss of $9.19 million in Q2 2026, which raises concerns about its financial health and sustainability.